Akums Drugs and Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹1,167cr+13.9% on Q1 FY26
Net profit
₹101cr+56.1% on Q1 FY26
EBITDA margin
15.0%+2.4 pts on Q1 FY26
EPS
₹6.53+57.3% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue1,1671,024+13.9%
EBITDA175129+35.4%
EBITDA margin15.0%12.6%+2.4 pts
Profit before tax13995.6+45.6%
Net profit10164.7+56.1%
EPS₹6.53₹4.15+57.3%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹1,167 crNet profit₹101 crNet margin8.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
11,065——
386386101
17.817.816.6
73.073.013.7
10,770——
4,5024,3594,118
—+5.8%—
568522464
12.6%12.0%11.3%
409367311
293256344
6.5%5.9%8.4%
₹19.05₹16.67₹22.09
—−24.5%—
—1,181465
—−231−272
951951193
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹722.70

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,065 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——11,064.9
- Cash, Equiv & ST Investments101.2386.0386.0
+ Minority Interest16.617.817.8
+ Total Debt13.773.073.0
Enterprise Value——10,769.6
Revenue4,118.24,359.04,501.6
Growth %, YoY—+5.8—
EBITDA464.5522.0567.7
Margin %11.2811.9812.61
EBIT311.0367.5409.0
Net Income343.8256.4292.7
Margin %8.355.886.50
EPS, Adj (current shares)22.0916.6719.05
Growth %, YoY—-24.5—
Cash from Operations465.21,181.2—
Capital Expenditures-272.3-230.5—
Free Cash Flow192.9950.7950.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Akums Drugs and Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Akums Drugs and Pharmaceuticals (NSE: AKUMS) had a market capitalisation of ₹11,346 crore at the 29 October 2026 close (₹741.05 a share), a PE ratio of 38.9 on the last four quarters' profit and a price-to-book ratio of 3.42. In FY26 its consolidated net profit attributable to shareholders was ₹255 crore on revenue of ₹4,359 crore; in Q1 FY27 (April–June 2026) it was ₹100 crore, up 57.6% year on year. Its debt-to-equity ratio was 0.02 on 31 March 2026. Promoters held 75.26% of the shares on 30 September 2026.

Share price used
₹741.05 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Akums Drugs and Pharmaceuticals at a glance · consolidated

Market cap
₹11,346 Crat ₹741.05 · 29 Oct close
PE ratio (last 4 quarters)
38.944.5 on FY26 profit
Price to book (PB)
3.42book value ₹216.41 a share
ROE (FY26)
8.0%ROCE 9.7%
Debt to equity
0.02net cash ₹1,608 Cr
Promoter holding
75.26%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.40%₹3 a share in 12 months
Net worth
₹3,313 Cr+8.7% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹951 Cr+392.9% vs FY25

Questions

What is the Akums Drugs and Pharmaceuticals PE ratio today?

Akums Drugs and Pharmaceuticals' PE ratio is 38.9 at the 29 October 2026 close (₹741.05 a share): a market capitalisation of ₹11,346 crore divided by consolidated net profit attributable to shareholders of ₹292 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹255 crore) it is 44.5.

What is the Akums Drugs and Pharmaceuticals PB ratio (price to book value)?

Akums Drugs and Pharmaceuticals' price-to-book (PB) ratio is 3.42 at the 29 October 2026 close: a market capitalisation of ₹11,346 crore divided by shareholders' equity (book value) of ₹3,313 crore on 31 March 2026. That is a book value of ₹216.41 per share against a share price of ₹741.05.

What is the Akums Drugs and Pharmaceuticals ROE and ROCE?

In FY26, Akums Drugs and Pharmaceuticals' return on equity (ROE) was 8.0% and its return on capital employed (ROCE) was 9.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the Akums Drugs and Pharmaceuticals market cap?

Akums Drugs and Pharmaceuticals' market capitalisation was ₹11,346 crore at the 29 October 2026 close: 15.31 crore shares at ₹741.05 each.

Is Akums Drugs and Pharmaceuticals debt free?

No. Akums Drugs and Pharmaceuticals had borrowings of ₹73 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.02. Its cash and current investments were ₹1,681 crore, so it held net cash of ₹1,608 crore.

What is the Akums Drugs and Pharmaceuticals debt to equity ratio?

Akums Drugs and Pharmaceuticals' debt-to-equity ratio was 0.02 on 31 March 2026: borrowings of ₹73 crore against total equity of ₹3,331 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Akums Drugs and Pharmaceuticals net worth?

Akums Drugs and Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,313 crore on 31 March 2026, up 8.7% from ₹3,047 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹11,346 crore at the 29 October 2026 close.

What is the Akums Drugs and Pharmaceuticals book value per share?

Akums Drugs and Pharmaceuticals' book value per share was ₹216.41 on 31 March 2026: shareholders' equity of ₹3,313 crore divided by the 15.31 crore shares in issue, up 8.8% from ₹198.98 a year earlier. The share price at the 29 October 2026 close was ₹741.05.

What is the Akums Drugs and Pharmaceuticals dividend yield?

Akums Drugs and Pharmaceuticals' dividend yield is 0.40% at the 29 October 2026 close: dividends of ₹3 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹741.05. They were ₹3 on 3 July 2026 (special).

What is the Akums Drugs and Pharmaceuticals EPS?

Akums Drugs and Pharmaceuticals' basic earnings per share (EPS) were ₹16.67 in FY26, against ₹22.60 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹19.05.

What is the Akums Drugs and Pharmaceuticals promoter holding?

Promoters held 75.26% of Akums Drugs and Pharmaceuticals on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

When are the Akums Drugs and Pharmaceuticals next results?

Akums Drugs and Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Akums Drugs and Pharmaceuticals dividend in 2026 and its record date?

In 2026, Akums Drugs and Pharmaceuticals has declared one dividend: ₹3 (special) with record date 3 July 2026.

What is the Akums Drugs and Pharmaceuticals free cash flow?

In FY26, Akums Drugs and Pharmaceuticals generated ₹1,181 crore of cash from operations and spent ₹231 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹951 crore. In FY25 it was ₹193 crore.

What are the Akums Drugs and Pharmaceuticals latest quarterly results?

Akums Drugs and Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 8 August 2026: consolidated net profit attributable to shareholders ₹100 crore, up 57.6% from ₹63.5 crore in Q1 FY26; revenue from operations ₹1,167 crore, up 13.9% year on year.

What is the Akums Drugs and Pharmaceuticals shareholding pattern?

On 30 September 2026, Akums Drugs and Pharmaceuticals' shares were held by promoters 75.26%, foreign portfolio investors (FII/FPI) 4.50%, domestic institutions (DII) 11.08% (including mutual funds at 7.58%) and retail and other non-institutional investors 6.43%. Over the year, FII holding was up 2.22 percentage points from 2.28% and DII holding was up 1.80 percentage points from 9.28%.

How does Akums Drugs and Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Dr. Agarwal's Health Care and Advanced Enzyme Tech: Akums Drugs and Pharmaceuticals' operating margin of 8.4% is the lowest of the three (Dr. Agarwal's Health Care 14.1%, Advanced Enzyme Tech 25.3%; peer average 19.7%); its return on equity of 8.0% is the second highest of the three (Dr. Agarwal's Health Care 6.8%, Advanced Enzyme Tech 11.1%; peer average 8.9%).

How does the Akums Drugs and Pharmaceuticals PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Akums Drugs and Pharmaceuticals' PE ratio is 44.5, the second highest of the three: Dr. Agarwal's Health Care 116.3 and Advanced Enzyme Tech 17.5, a peer average of 66.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the Akums Drugs and Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Akums Drugs and Pharmaceuticals' consolidated net profit attributable to shareholders was ₹255 crore, down 24.5% from ₹338 crore in FY25, on revenue from operations of ₹4,359 crore (up 5.8%).

Akums Drugs and Pharmaceuticals vs Dr. Agarwal's Health Care: how do they compare?

In FY26, Akums Drugs and Pharmaceuticals earned net profit attributable to shareholders of ₹255 crore on revenue of ₹4,359 crore, against ₹133 crore on ₹2,080 crore for Dr. Agarwal's Health Care. Akums Drugs and Pharmaceuticals' operating margin was 8.4% (Dr. Agarwal's Health Care 14.1%) and its return on equity 8.0% (Dr. Agarwal's Health Care 6.8%). At the 29 October 2026 close, Akums Drugs and Pharmaceuticals' market capitalisation was ₹11,346 crore against ₹15,492 crore for Dr. Agarwal's Health Care, and its PE ratio on FY26 profit 44.5 against 116.3.

Where do these Akums Drugs and Pharmaceuticals figures come from?

From Akums Drugs and Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.